All News
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read Article
Exploring Idiopathic Myopathies
Idiopathic inflammatory myopathies (IIM) are a heterogenous group of autoimmune conditions with substantial morbidity. EULAR in collaboration with the American College of Rheumatology (ACR) introduced classification criteria for the major subgroups in 2017,1 but there is a need for contemporary real-world data to understand the burden – and well as new ways of assessing disease activity.
Read Article
‘Strong’ treatment predictions in inflammatory myositis
Presented at EULAR 2026 London, Brepocitinib dual TYK2/JAK1 inhibitor with successful Phase 3 VALOR trial demonstrating significant improvement in skin and muscle symptoms in dermatomyositis (DM).
Read Article
Digital Platforms and AI
EULAR works with the network of national organisations of People with Arthritis/Rheumatism in Europe (PARE) to ensure the voices of people with RMD are heard and have influence – creating powerful alliances that make a real difference. Artificial intelligence is another potential ally in that fight. At the EULAR 2026 Congress in London, work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions.
Read Article
Follow the Money (4.23.2026)
Dr. Jack Cush follows the money and all the news that fits the Rheumatology Gab for this past week.
Read Article
Prescribing Lessons (4.17.2026)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Top Four and More (4.10.2026)
Dr. Jack Cush reviews the news and journal reports from RheumNow.com this week - including his top four favorite subjects.
Read Article
Predictors of Calcinosis Cutis in Systemic Sclerosis
Calcinosis cutis (CaC) is a common and disabling non-lethal manifestations in systemic sclerosis (SSc). This study used SSc patients from the EUSTAR database to clinically characterize patients and identify risk factors for CaC development.
Read Article
What’s New PsA? (4.3.2026)
Dr. Jack Cush reviews the news and major articles from this week, including FDA safety warnings, reports from AAD, PsA trials.
Read Article
Brepocitinib in Dermatomyositis
The NEJM reports that brepocitinib, an oral TYK2–JAK1 inhibitor, was studied in a phase 3 trial of refractory dermatomyositis (DM) patients and shown to have significant benefits at the higher dose.
Read Article
Links:
#EULAR2026 OP0170 Progress of CAR-T in myositis? Phase 1 of rese-cel autologous CD19 CAR-T (advantage: humanised, 4-1BB Co-stimulatory Domain to enhance cells expansion) showed no safety signals and early efficacy in 4 IIM subtypes. Both anti-synthetase pts relapsed @RheumNow https://t.co/QisldedCti
#EULAR2026 OP076 Of 50 patients treated with autologous CAR-T, 12% relapsed; median 13 mths. More frequent in #IIM vs #SLE or #SSc. These relapses were significant. Switching to BCMA-CAR or BCMA-TCE restored response. Should BCMA instead of CD19 be targeted initially?@RheumNow https://t.co/lgdsJQm3xY
Links:
